share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

再生元製藥公司 | 4：持股變動聲明-董事 Thompson Craig B.
美股SEC公告 ·  01/07 05:13

牛牛AI助理已提取核心訊息

On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
在2025年1月2日，湯普森·克雷格與再生元製藥公司相關，獲得了166股普通股，每股價格爲0美元，通過贈予或獎勵進行。該交易已報告完成。此次收購後，湯普森·克雷格對再生元普通股的直接持有量增加至620股。這些股票以「直接」所有權形式收購，表明是個人所有，而非通過中介或相關實體。
在2025年1月2日，湯普森·克雷格與再生元製藥公司相關，獲得了166股普通股，每股價格爲0美元，通過贈予或獎勵進行。該交易已報告完成。此次收購後，湯普森·克雷格對再生元普通股的直接持有量增加至620股。這些股票以「直接」所有權形式收購，表明是個人所有，而非通過中介或相關實體。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間